Press release archive - GSK
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Press releases | GSK US
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease.
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
3 days ago · In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday ...
GSK lifts annual forecasts again, powered by strong vaccine launch
Nov 1 (Reuters) - GSK (GSK.L) raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the...
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
LONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...
For media and investors only - GSK
Jun 23, 2021 · At an update to investors today, GlaxoSmithKline plc (GSK LSE & NYSE) will provide details of its strategy, outlook for growth and plans to create shareholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business.
GlaxoSmithKline News | GSK News - NewsNow
NewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications.
GSK delivers strong 2022 performance with full year sales of £29.3 ...
Feb 1, 2023 · Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines. Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions.